NO20080626L - Inhibitorer av fibroblastaktiverende protein alfa - Google Patents
Inhibitorer av fibroblastaktiverende protein alfaInfo
- Publication number
- NO20080626L NO20080626L NO20080626A NO20080626A NO20080626L NO 20080626 L NO20080626 L NO 20080626L NO 20080626 A NO20080626 A NO 20080626A NO 20080626 A NO20080626 A NO 20080626A NO 20080626 L NO20080626 L NO 20080626L
- Authority
- NO
- Norway
- Prior art keywords
- protein alpha
- inhibitors
- activating protein
- fibroblast activating
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69677205P | 2005-07-05 | 2005-07-05 | |
| PCT/US2006/026258 WO2007005991A1 (en) | 2005-07-05 | 2006-07-05 | Inhibitors of fibroblast activation protein alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20080626L true NO20080626L (no) | 2008-04-02 |
Family
ID=37604810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20080626A NO20080626L (no) | 2005-07-05 | 2008-02-04 | Inhibitorer av fibroblastaktiverende protein alfa |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7998997B2 (enExample) |
| EP (1) | EP1898899A4 (enExample) |
| JP (2) | JP5229897B2 (enExample) |
| KR (1) | KR20080030079A (enExample) |
| CN (1) | CN101247799B (enExample) |
| AU (1) | AU2006264305B2 (enExample) |
| BR (1) | BRPI0612607A2 (enExample) |
| CA (1) | CA2613795A1 (enExample) |
| IL (2) | IL188327A0 (enExample) |
| MX (1) | MX2008000318A (enExample) |
| NO (1) | NO20080626L (enExample) |
| WO (1) | WO2007005991A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2606785A1 (en) * | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| EP1760076A1 (en) * | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
| KR20140042933A (ko) | 2007-08-06 | 2014-04-07 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 프로테아좀 억제제 |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| US7838673B2 (en) | 2007-10-16 | 2010-11-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| EP2212334B1 (en) * | 2007-10-16 | 2012-08-15 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| SI2318419T2 (sl) | 2008-06-17 | 2025-10-30 | Takeda Pharmaceutical Company Limited | Spojine boronat estra in njihovi farmacevtski sestavki |
| AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| AU2011235227B2 (en) | 2010-03-31 | 2016-09-08 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| EP4706663A3 (en) * | 2011-08-30 | 2026-05-20 | Trustees Of Tufts College | FAP-ACTIVATED PROTEASOME INHIBITORS USED TO TREAT SOLID TUMORS |
| US9284337B2 (en) * | 2011-11-22 | 2016-03-15 | Trustees Of Tufts College | Small molecule enhancer for dendritic cell cancer vaccines |
| WO2014022636A1 (en) * | 2012-08-02 | 2014-02-06 | Trustees Of Tufts College | Broad spectrum inhibitors of the post proline cleaving enzymes for treatment of hepatitis c virus infections |
| UA121389C2 (uk) | 2014-05-20 | 2020-05-25 | Мілленніум Фармасьютікалз, Інк. | Борвмісні інгібітори протеасом для застосування після первинної протиракової терапії |
| CZ2014527A3 (cs) * | 2014-08-05 | 2016-02-17 | Ústav Organické Chemie A Biochemie Akademie Věd Čr, V.V.I. | Způsob detekce aktivní formy analytů ve vzorku a stanovení schopnosti dalších látek vázat se do aktivních míst těchto analytů |
| MA41505A (fr) | 2015-02-11 | 2017-12-19 | Millennium Pharm Inc | Nouvelle forme cristalline d'un inhibiteur de protéasome |
| WO2016171446A1 (ko) * | 2015-04-20 | 2016-10-27 | 동아에스티 주식회사 | 펩타이드 붕소산 화합물을 함유하는 안정화 약학 제제 |
| CN106588965A (zh) | 2015-10-15 | 2017-04-26 | 北京大学 | 脲拟肽硼酸化合物及其药物组合物、制备方法和用途 |
| JP6223508B2 (ja) * | 2016-06-27 | 2017-11-01 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | プロテアソーム阻害剤 |
| JP7162592B2 (ja) | 2016-12-14 | 2022-10-28 | パーデュー・リサーチ・ファウンデイション | 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療 |
| WO2018129497A1 (en) | 2017-01-09 | 2018-07-12 | Bioxcel Therapeutics, Inc. | Predictive and diagnostic methods for prostate cancer |
| CN108929340B (zh) * | 2017-05-22 | 2019-12-13 | 北京大学 | 脯氨酸硼酸类化合物及其制备方法和用途 |
| WO2019154859A1 (en) * | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Fap inhibitor |
| MX2022011842A (es) * | 2020-03-24 | 2022-10-20 | Tufts College | Agentes de imagen y radiofarmacos dirigidos a fap, y usos relacionados con los mismos. |
| EP4313033A4 (en) * | 2021-03-24 | 2025-04-23 | Trustees Of Tufts College | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS |
| CN118955616B (zh) * | 2024-05-01 | 2025-09-02 | 杭州景嘉航生物医药科技有限公司 | 一种靶向结合成纤维细胞活化蛋白化合物及应用 |
| CN119390720B (zh) * | 2024-12-31 | 2025-04-01 | 杭州景嘉航生物医药科技有限公司 | 一种靶向结合成纤维细胞活化蛋白的双环[1.1.1]戊烷类化合物及其应用 |
| WO2026007968A1 (zh) * | 2024-07-01 | 2026-01-08 | 杭州景嘉航生物医药科技有限公司 | 一种靶向结合成纤维细胞活化蛋白的化合物及应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US497A (en) * | 1837-12-01 | Improvement in the machine for preparing ice for shipping and storing | ||
| US4935493A (en) * | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
| US5106948A (en) | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
| US4963655A (en) | 1988-05-27 | 1990-10-16 | Mayo Foundation For Medical Education And Research | Boron analogs of amino acid/peptide protease inhibitors |
| US5159060A (en) * | 1988-05-27 | 1992-10-27 | Mayo Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
| EP1463719A2 (en) * | 2002-01-08 | 2004-10-06 | Eisai Co., Ltd | Eponemycin and epoxomicin analogs and uses thereof |
| US7691967B2 (en) * | 2002-04-30 | 2010-04-06 | Trustees Of Tufts College | Smart pro-drugs of serine protease inhibitors |
| WO2004004661A2 (en) * | 2002-07-09 | 2004-01-15 | Point Therapeutics, Inc. | Boroproline compound combination therapy |
| WO2004050613A2 (en) * | 2002-12-02 | 2004-06-17 | Gilead Sciences, Inc. | 2-substituted-3-propenamide derivatives and methods of using the same |
| US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| AU2004288831B2 (en) * | 2003-11-12 | 2010-08-26 | Phenomix Corporation | Heterocyclic boronic acid compounds |
| CA2606785A1 (en) * | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
-
2006
- 2006-07-05 CN CN2006800307719A patent/CN101247799B/zh not_active Expired - Fee Related
- 2006-07-05 AU AU2006264305A patent/AU2006264305B2/en not_active Ceased
- 2006-07-05 US US11/994,707 patent/US7998997B2/en not_active Expired - Fee Related
- 2006-07-05 KR KR1020087002781A patent/KR20080030079A/ko not_active Ceased
- 2006-07-05 JP JP2008520373A patent/JP5229897B2/ja not_active Expired - Fee Related
- 2006-07-05 EP EP06786415A patent/EP1898899A4/en not_active Withdrawn
- 2006-07-05 MX MX2008000318A patent/MX2008000318A/es active IP Right Grant
- 2006-07-05 BR BRPI0612607-3A patent/BRPI0612607A2/pt not_active Application Discontinuation
- 2006-07-05 WO PCT/US2006/026258 patent/WO2007005991A1/en not_active Ceased
- 2006-07-05 CA CA002613795A patent/CA2613795A1/en not_active Abandoned
-
2007
- 2007-12-20 IL IL188327A patent/IL188327A0/en unknown
-
2008
- 2008-02-04 NO NO20080626A patent/NO20080626L/no not_active Application Discontinuation
-
2011
- 2011-07-06 US US13/177,268 patent/US20120077779A1/en not_active Abandoned
-
2012
- 2012-01-17 IL IL217579A patent/IL217579A/en not_active IP Right Cessation
- 2012-02-20 JP JP2012033777A patent/JP2012140439A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006264305B2 (en) | 2012-07-05 |
| CN101247799A (zh) | 2008-08-20 |
| IL217579A (en) | 2013-04-30 |
| EP1898899A1 (en) | 2008-03-19 |
| JP2009500423A (ja) | 2009-01-08 |
| CN101247799B (zh) | 2013-03-27 |
| IL188327A0 (en) | 2008-04-13 |
| AU2006264305A1 (en) | 2007-01-11 |
| JP5229897B2 (ja) | 2013-07-03 |
| EP1898899A4 (en) | 2009-07-29 |
| MX2008000318A (es) | 2008-03-11 |
| JP2012140439A (ja) | 2012-07-26 |
| BRPI0612607A2 (pt) | 2010-12-07 |
| CA2613795A1 (en) | 2007-01-11 |
| US7998997B2 (en) | 2011-08-16 |
| US20090221818A1 (en) | 2009-09-03 |
| WO2007005991A1 (en) | 2007-01-11 |
| US20120077779A1 (en) | 2012-03-29 |
| KR20080030079A (ko) | 2008-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008001234A1 (es) | Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer. | |
| EA200801301A1 (ru) | ИНГИБИТОРЫ АКТИВНОСТИ Akt | |
| JO3235B1 (ar) | مركبات بيررولوبيريميدين و استعمالاتها | |
| IL257622B (en) | Methods and compositions for the treatment of persistent infections | |
| CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
| CY1115535T1 (el) | Αναστολεις δραστικοτητας ακτ | |
| BRPI0809583A2 (pt) | polipeptídeos fgf-21 modificados e seus usos | |
| NO20081636L (no) | FAP - inhibitorer | |
| EA200901313A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| ATE524459T1 (de) | Pyrazolederivate und ihr einsatz als hemmer von cyclinabhängigen kinasen | |
| EA201000094A1 (ru) | Производные пиримидинил-пиридазинона | |
| CL2011001536A1 (es) | Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
| CY1112206T1 (el) | Παραγωγα πυριδαζινονης για την θεραπεια ογκων | |
| CL2008001076A1 (es) | Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2011001215A1 (es) | Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes. | |
| ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
| CL2008002369A1 (es) | Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer. | |
| CL2011002300A1 (es) | Compuestos derivados de 2,4-diamiropirimidinas 5-sustitudas inhibidoras de quinasa ptk2; preparaciones farmaceuticas; y su uso para el tratamiento y/o la prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes. | |
| DK1866324T3 (da) | Phosphoramidatderivater af nukleosidforbindelser til anvendelse i behandlingen af cancer | |
| CY1109741T1 (el) | Sns-595 και μεθοδοι χρησης αυτου | |
| CL2007002384A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis. | |
| CL2008001038A1 (es) | Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano | |
| CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
| ECSP099634A (es) | Derivados de piridazinona útiles como inhibidores de glucano sintasa | |
| ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |